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Rationale
Serum biomarker analysis is a valuable noninvasive tool
for assessment of asthma severity in children. Surfactant
protein D (SP-D) is an immunoprotective lung collectin
produced in the lung in large quantities. We have pre-
viously shown that allergen-induced airway inflammation
was associated with significant changes of SP-D release
and that glucocorticoid therapy increases SP-D in the
lung. Whether such changes could be detected in the
peripheral circulation of asthmatic patients is not known.
We hypothesized that serum SP-D would reflect disease
severity in asthmatic children.
Methods
SP-D and IL-13 serum levels were measured in 122
patient samples and 22 samples from non-asthmatic
controls. Serum was collected from peripheral blood of
25 children with asthma (diagnosed according to the
American Thoracic Society criteria), that was inade-
quately controlled according to European Consensus
Guidelines, as described previously by Gemou-Engesaeth
et al., 2002. Children were characterized as atopic (17)
and as nonatopic (8). Their age was between 7 and 16
years. In addition 15 nonasthmatic controls matched for
age and atopic status were included in the study. SP-D
was assessed in duplicate samples in two dilution (1:5
and 1:10) using a commercially available human SP-D
ELISA kit (BioVendor). IL-13 was assessed using a kit
from RayBiotech, Inc.Measurements were repeated in 17
of the asthmatics 4 to 6 months after initiation or esca-
lation of inhaled glucocorticoid therapy (in 10) and after
initiation of inhaled Sodium Cromoglycate(in 7) for
inadequately controlled asthma.
Results
The inter-assay and inter-experimental variability of the
measures was <10%. IL-13 levels varied between 0-171
pg/ml. SP-D levels varied between 19-373 ng/ml. The
expression of IL-13 was significantly greater in the asth-
matic serum samples than in the controls (25.6±2.7 vs.
14.3±2.0 p=0.0011, 2-tail t test, unequal variability).
In contrast, SP-D levels were significantly greater in the
control samples than in the asthmatic samples (148.2±5.9
vs. 200.2±20.2; p=0.0478). Treatment with glucocorticoids
or sodium cromoglycate did not affect IL-13 or SP-D in
the serum although in the sodium cromoglycate treated
patients there was a trend for reduced IL-13.
Conclusions
These data indicate that serum levels of IL-13 and SP-D
correlate with the presence of allergic airways disease in
children. We speculate that these biomarkers may provide
useful noninvasive indicators that reflect disease state in
moderate to severe childhood asthma.
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